NL-OMON43801已完成3 期
201956: A Long-term Access Programme for Subjects with Severe Asthma who Participated in a GSK-sponsored Mepolizumab Clinical Study - 201956
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Participated in GSK-sponsored asthma clinical study with mepolizumab as specified in the protocol, appendix 2.
- •1. completed the treatment period in the mepolizumab asthma clinical study to which they were originally enrolled
- •2. if the subject was withdrawn from study treatment prematurely during the mepolizumab asthma clinical study to which they were originally enrolled but the subject has completed the study assessments at the study visit that would have been the end of the respective treatment period.
- •The treating physician considers the benefits of treatment with mepolizumab outweigh the risks for the individual subject.
- •Adequate contraception for females of childbearing potential.
排除标准
- •Subject had an adverse event (serious or non-serious) considered related to study treatment whilst participating in a clinical study with mepolizumab which resulted in permanent withdrawal of study treatment.
- •Treatment with another biological therapy.
- •Treatment with an investigational drug within the past 30 days or 5 terminal phase half-lives.
- •Current participation in any other interventional clinical study.
- •Pregnancy or breastfeeding
研究者
相似试验
进行中（未招募）
1 期
A Long-term Access Programme for Asthmatic Subjects who Participated in a Clinical Study with MepolizumabSubjects with severe asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-001152-29-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT550
已完成
不适用
201956: A LONG-TERM ACCESS PROGRAMME FOR SUBJECTS WITH SEVERE ASTHMA WHO PARTICIPATED IN A GSK-SPONSORED MEPOLIZUMAB CLINICAL STUDYPER-067-15GlaxoSmithKline,13
进行中（未招募）
1 期
A Long-term Access Programme for Asthmatic Subjects who Participated in a Clinical Study with MepolizumabSubjects with severe asthmaMedDRA version: 19.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-001152-29-DEGlaxoSmithKline Research & Development Ltd550
进行中（未招募）
1 期
A Long-term Access Programme for Asthmatic Subjects who Participated in a Clinical Study with MepolizumabSubjects with severe asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-001152-29-PLGlaxoSmithKline Research & Development Ltd550
进行中（未招募）
1 期
A Long-term Access Programme for Asthmatic Subjects who Participated in a Clinical Study with MepolizumabEUCTR2015-001152-29-BEGlaxoSmithKline Research & Development Ltd550